Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The Cooper Companies Inc. (COO - Analyst Report), a company focused on contact lens and women’s health, recently revealed that CooperVision had reached an agreement to divest Aime. This Aime unit runs a contact lens operation in Japan. It will be sold to Nippon Contact Lens Inc. The company did not reveal the terms of the sale. 

Aime is a manufacturer of rigid lenses. Cooper stated that the decision to divest it was in line with its policy to focus on soft contact lenses. Furthermore, Aime had shrinking sales and its margin was on the lower side. Aime had revenues of $32.9 million in fiscal 2012.   

The sale of the Aime unit is expected to culminate in Cooper’s fiscal fourth quarter 2013. The company anticipates that the sale will adversely affect its fiscal 2013 reported earnings per share by 25 cents to 35 cents.

Cooper, a global company, specializes in a wide range of contact lenses for the vision correction market with a smaller strategic business unit for women’s health. It holds a leading position in the global contact lens industry.

The outlook for the contact lens industry is favorable. Trade up to value added lenses, such as silicone hydrogel or one-day lenses, constitutes a major avenue for growth. A trade up to 1-day disposable lenses sharply increases per user sales and profit. Trade up to the company’s flagship Biofinity silicone hydrogel offering has been a success.

Cooper is a leader in the high-margin toric lens market. It offers multiple designs of toric lenses across a wide range of parameters, unlike some of its competitors, who offer toric lenses in a limited number of designs.

However, Cooper faces formidable competition in each of its major product lines. Competition comes from well established global contact lens makers. Depressed levels of consumer spending have heightened the company’s competitive pressures.

The stock currently carries a Zacks Rank #2 (Buy). We are also positive about Becton, Dickinson and Company (BDX - Analyst Report), Conmed Corporation (CNMD - Analyst Report) and Steris Corp. (STE - Snapshot Report) each of which carries a Zacks Rank #2 (Buy) and are expected to do well.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.00 +13.50%
ATLAS FINANC AFH 14.57 +2.32%
FEDERATED NA FNHC 20.30 +2.16%
BIO PATH HOL BPTH 2.75 +1.48%
GREEN PLAINS GPRE 29.33 +1.31%